安罗替尼联合PD-1抑制剂治疗晚期卵巢癌临床转归的影响因素及其预测效能

打开文本图片集

[关键词]卵巢肿瘤；程序性细胞死亡受体1;安罗替尼；治疗结果;影响因素分析[中图分类号] R737.31；R392.1 ［文献标志码］A [文章编号] 2096-5532（2025）03-0406-05doi：10.11712/jms.2096-5532.2025.61.091 [开放科学（资源服务）标识码（OSID）][网络出版] https：//link.cnki.net/urlid/37.1517.R.20250724.1407.001; 2025-07-2417：18：18

Influencingfactorsfortreatmentoutcomeofanlotinibcombined withPD-1inibitors inadvanced epithelialovariancancerandtheir predictive eficacyGETan，SHEN Jian，ZHAORong（Pharmacy Departmentof Ruijin Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 20o025，China）

[Abstract]ObjectiveTo investigate thefactors influencing the clinicaloutcomeof anlotinib combined with programmed death-1（PD-1）inibitors treatingadvancedepithelialovariancancer（EOC）andtheirpredictiveeficacy.MethodsWedivided 157 patientswithadvancedEOCtreatedwithanlotinibcombinedwithPD-1inhibitorsinourhospitalfromAugust202OtoAugust 2023intogoodoutcome groupand pooroutcomegroup.Basedonthepatients’clinicaland biochemical data，thefactorsaffecting clinicaloutcome wereanalyzed，andtheirpredictiveeficacywasaessed.ResultsHighgradeserouscarcioma，aphsicalsta tus（PS） score of 2 points，PD-Ll expression ≥1% ，highcarbohydrate antigen 125（CA125）levels，and high human epididymis protein 4（HE4） levels were independent risk factors for the clinical outcome of advanced EOC（ OR=1.730-2.109，P<0.05 ） Combining pathologicaltype，PSscore，PD-L1，CAl25，andHE4forclinicaloutcomeprediction，theareaunderthereceiverope rating characteristic curve was O.873，with a sensitivity of 95.65% and a specificity of 70.00% . ConclusionPathological type， PD-L1，CA125，HE4，andPSscoreareindependentfactorinfluencingtheclinicaloutcomeofanlotinibplusPD-1inibitors treating advanced EOC，which demonstrate high predictive efficacy when combined.

[Key words]ovarian neoplasms；programmed celldeath 1receptor；anlotinib；treatment outcome;root cause analysis

上皮性卵巢癌（EOC）为女性常见的恶性肿瘤，多起源于卵巢表面上皮细胞，可分为高级别浆液性癌、子宫内膜样癌、透明细胞癌和黏液性癌等，其中高级别浆液性癌最为常见[1]。（剩余7457字）